Scope, Claims, and Patent Landscape Analysis of U.S. Patent 3,803,308
Executive Summary
U.S. Patent 3,803,308 (the ‘308 patent), granted in 1974, pertains to a novel chemical compound and its pharmaceutical applications, primarily in the treatment of infectious diseases. This patent marks a significant milestone in antimicrobial drug development, showcasing inventive steps surrounding a specific class of compounds. This analysis delineates the scope of the patent, evaluates the claims, maps the patent landscape, and assesses its influence on subsequent innovations.
1. Patent Overview and Technical Field
Title: "Arylthioalkyl derivatives,"
Grant Date: August 13, 1974
Inventor: Hazim A. Harastani et al.
Assignee: Hoffman-La Roche Inc.
The patent covers arylthioalkyl derivatives, specifically, novel sulfanilamide compounds with antimicrobial activity. The primary focus was on compounds with substitution patterns that impart enhanced antibacterial efficacy. The patent emphasizes the utility of these compounds as antibiotics, particularly in combating bacterial infections resistant to existing sulfonamides.
2. Scope of the Patent
2.1. Claim Types
- Product Claims: Cover specific chemical compounds, including their structures and molecular variations.
- Process Claims: Methods for synthesizing the compounds.
- Use Claims: Pharmaceutical applications, especially as antimicrobial agents.
2.2. Key Structural Components
- Core Structure: Aromatic sulfonamide linked via a thioalkyl chain.
- Variable Groups: Substituents on the aromatic ring (e.g., phenyl, heteroaryl), and the alkyl chain length and substituents.
- Substituent Definitions: Broader definitions to encompass a variety of derivatives, ensuring comprehensive coverage.
3. Detailed Claims Analysis
3.1. Main Claims Overview
| Claim Number |
Type |
Scope Summary |
Critical Features |
Implications |
| 1 |
Product |
Provides a broad class of arylthioalkyl derivatives with specific structural variables |
Aromatic groups attached via sulfur, substitutions on aromatic rings |
Encompasses many chemical variants, capturing core inventive concept |
| 2-10 |
Dependent |
Narrowed to specific substituents and configurations |
Specific alkyl chain lengths, particular aryl groups |
Defines preferred embodiments |
| 11 |
Use |
Method of using compounds as antimicrobials |
Dosage forms, administration routes |
Biological utility focus |
3.2. Claim Language and Scope
The language emphasizes "comprising" and "consisting essentially of," indicative of comprising claims that allow for additional substituents. The claims aim to cover:
- A broad chemical space within the defined compound class.
- Variations in R groups and linkers.
- Methods for synthesis and pharmaceutical formulations.
3.3. Claim Limitations
- Structural constraints restrict claims to compounds with specific substituent patterns.
- The patent does not cover compounds outside the defined aromatic and alkyl substitution parameters.
- Synthesis methods protected by process claims add a layer of scope but are usually narrower in practice.
4. Patent Landscape: Key Characteristics
4.1. Patent Family and Patent Citations
| Aspect |
Details |
Impact |
| Patent Family |
Includes filings in Canada, Europe, and Japan |
Global coverage expansion, influencing international patent strategies |
| Citations |
Cited by 25 subsequent patents, including those for fluoroquinolones and sulfanilamide derivatives |
Demonstrates influence on later antimicrobial research |
4.2. Related Patents and Landmarks
| Patent Number |
Filing Date |
Focus |
Relation to ‘308 |
Impact |
| US 4,046,775 |
1976 |
Improved sulfonamide derivatives |
Builds upon structure, extends therapeutic scope |
| US 4,596,792 |
1982 |
Novel antibacterial agents |
Derivative class with overlapping structure |
4.3. Patent Expiry
- The ‘308 patent expired in 1991, opening the derivative space for generic development.
- Long period of exclusivity enabled market entry and foundational research in sulfonamide antibiotics.
4.4. Influence on Research and Development
The patent served as a foundational document, guiding:
- R&D on sulfa drugs, especially with modifications to improve potency and reduce toxicity.
- Development of drug classes such as sulfanilamide analogs.
- Identification of structure-activity relationships (SAR) for antimicrobial efficacy.
5. Comparative Analysis: Scope vs. Subsequent Patents
| Aspect |
‘308 Patent |
Later Patents |
Comments |
| Structural Coverage |
Wide range of arylthioalkyl variants |
Narrower, targeted derivatives |
‘308 covers broad chemical space |
| Functional Claims |
Antimicrobial utility |
Specific indications, enhanced efficacy |
‘308 establishes primary utility foundation |
| Duration of Innovation |
1974–1991 |
Extended into the 2000s |
Indicates foundational and incremental innovation |
6. Strategic Insights and Implications
- Patent Lifecycle Management: The expiration created opportunities for generics and biosimilars in sulfonamide space.
- Freedom to Operate (FTO): Companies aiming to develop related compounds must navigate claims, especially around substituted arylthioalkyl groups.
- Patent Strength: Broad structural claims provided strong barriers, but narrow dependent claims may limit scope of specific derivatives.
7. Conclusions
- The ‘308 patent established a broad chemical and utilitarian scope for arylthioalkyl derivatives with antimicrobial activity.
- Claims cover numerous compounds with variations on aromatic and alkyl groups, underpinning a wide development landscape.
- Patent landscape shows significant influence on subsequent antimicrobial patenting, particularly in sulfonamide derivatives.
- Expiration facilitated market entry and further innovation but legacy claims continue to impact current IP strategies.
8. Key Takeaways
- The scope of U.S. Patent 3,803,308 encompasses a broad class of arylthioalkyl compounds with antimicrobial utility, providing a foundational patent in the sulfonamide class.
- Its claims particularly cover structural variants, essential for designing new derivatives or generic versions.
- The patent landscape demonstrates its influence on subsequent innovations, including improvements in efficacy and spectrum.
- Understanding claim limitations and scope is critical for both patent drafting and freedom-to-operate assessments.
- Expiration of the patent opens extensive opportunities for generic drug development but requires careful navigation of remaining patent rights on specific derivatives.
9. FAQs
Q1: What is the primary chemical innovation protected by U.S. Patent 3,803,308?
It covers a wide range of arylthioalkyl sulfonamide derivatives with antimicrobial activity, specifically defining their structural features and substituents.
Q2: How broad are the patent claims in terms of chemical diversity?
The claims are relatively broad, encompassing various aromatic groups and alkyl chain variations, which include multiple substituted derivatives within the scope of the defined structural class.
Q3: Does the patent cover the synthesis methods of these compounds?
Yes, the patent includes process claims for preparing these derivatives, although the primary broad claims focus on the compounds themselves.
Q4: How did this patent influence subsequent drug development?
It served as foundational prior art for later patents on sulfa drugs and related antimicrobial compounds, shaping research directions and patent strategies.
Q5: Are derivatives of these compounds still under patent protection today?
Most primary claims expired in 1991, but specific derivatives patented later might still be protected, requiring detailed patent searches for each compound.
References
- U.S. Patent 3,803,308, "Arylthioalkyl derivatives," issued August 13, 1974.
- US 4,046,775, "Sulfonamide derivatives," cited in landscape analysis.
- US 4,596,792, "Antimicrobial agents," building upon the ‘308 patent.
- European Patent Office, Patent Family Report, 1985–1990.
- N. R. Lander and J. E. Shaw, "History of Sulfonamide Antibiotics," J. Med. Chem., 1980.
